Kinimmune

Kinimmune is a private, clinical-stage biotech founded in 2020 and based in Cambridge, USA, targeting the significant unmet need in solid tumor immunotherapy. The company's core approach involves formulating intratumoral immunostimulants with improved tissue retention to safely 'step on the gas' of the immune system, thereby unlocking the full potential of checkpoint blockade. With a pipeline featuring both 505(b)(2) and new chemical entity (NCE) programs, Kinimmune aims to broaden the therapeutic window and improve patient outcomes. The company is currently pre-revenue, advancing its lead asset, KIN-101, into clinical development.

Proprietary drug formulation platform for creating tissue-retentive intratumoral immunostimulants, designed to maximize local immune activation in the tumor microenvironment while minimizing systemic exposure and toxicity.

Kinimmune competes in the crowded intratumoral immunotherapy space, which includes companies developing oncolytic viruses (e.g., Amgen's Imlygic), cytokine formulations, TLR agonists, and other localized immunostimulants. Key differentiators are Kinimmune's focus on tissue-retentive formulations to improve safety and its strategic use of the 505(b)(2) pathway for accelerated development.